Industry Research
-
Interest In Hybrid Trials Increases
5/3/2021
While outsourcing respondents currently hold mixed opinions on conducting hybrid trials, over two-thirds either currently use or plan to use them in the next two years.
-
Outsourcing Drivers For Small Molecule Manufacturing
4/1/2021
ISR’s recent survey of small molecule outsourcers found that the majority of respondents outsource for one of two reasons: for all of their manufacturing needs, or to augment their internal manufacturing capacity.
-
Insights On How Outsourcing Decisions Are Made
4/1/2021
How does your company’s approach to making outsourcing decisions compare with others in the industry? Data from ISR’s CDMO outsourcing models report highlights common practices that, when adopted, may improve outsourcing outcomes from drug innovators’ perspectives.
-
Sources For Clinical Outcome Reporting And Assessments
3/1/2021
In a recent survey of respondents familiar with eCOA and ePRO systems, ISR asked about respondents’ past and projected use patterns regarding both the source of clinical reported outcomes and the source of clinical outcomes assessments (COAs).
-
CMOs Continue To Exceed Sponsor Expectations
3/1/2021
ISR explains how the CMO Leadership Awards and the corresponding market research data can be used to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.
-
Number Of EDC Systems Used — Current And Projected
2/1/2021
In our most recent survey of EDC users, respondents indicated they are currently using 2.4 EDC systems on average to conduct their companies’ clinical trials.
-
Sponsor Interest In Current Phase 1 Trends
1/4/2021
We asked respondents their level of agreement regarding several trends in the Phase 1 space to assess the direction in which their organization’s interest is heading.
-
Phase 2/3 Outsourced Spend By Provider Type
12/1/2020
ISR asked respondents responsible for outsourcing Phase 2/3 drug development how they allocate their outsourcing budget toward CROs of various sizes and academic medical centers.
-
Top 5 Challenges In Finding Rare Disease Patients
10/30/2020
ISR asked respondents with involvement in patient recruitment and retention activities for Phase 2/3 rare disease studies about their pain points regarding patient recruitment.
-
PPA Differences Between Small And Large Sponsors
10/1/2020
The overwhelming majority of small and emerging biopharma companies do not have preferred provider agreements (PPAs) for Phase 2/3 outsourcing. What does this mean?